Assessing Early Behavioral Indicators of Formula Tolerance
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Children's Nutrition Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singleton at birth
- Term infant with birth weight of 2500 g or more
- Crying or fussing for 3 or more hours per day
- Consuming mostly infant formula
- Signed Informed Consent and Protected Health Information authorization
Exclusion Criteria:
- Current use of extensively hydrolyzed or amino acid infant formula
- Planned use of probiotics during the study
- History of underlying metabolic or chronic disease, congenital malformation, or immunocompromised
- Enrollment in another interventional clinical research study
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control
Marketed partially hydrolyzed cow's milk protein infant formula
|
Marketed partially hydrolyzed cow's milk protein infant formula
|
|
Experimental: Investigational
Partially hydrolyzed cow's milk infant formula with a probiotic
|
Partially hydrolyzed cow's milk protein infant formula with a probiotic
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Infant Behavior Diary
Time Frame: 21 Days
|
21 Days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recall of Tolerance Questionnaire
Time Frame: Baseline and Day 21
|
Baseline and Day 21
|
|
Body Weight
Time Frame: Baseline and Day 21
|
Baseline and Day 21
|
|
Infant Behavior Questionnaire - Revised
Time Frame: Baseline and Day 21
|
Baseline and Day 21
|
|
Recall of formula intake at each visit
Time Frame: Baseline, Day 10, and Day 18
|
Baseline, Day 10, and Day 18
|
|
Fecal microbiome and Fecal calprotectin
Time Frame: Baseline and Day 21
|
Baseline and Day 21
|
|
Medically-confirmed Adverse Events
Time Frame: 21 Days
|
21 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Carol Lynn Berseth, M.D., Mead Johnson Nutrition
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 6025
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.